PMID- 30431595
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20240404
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 46
DP  - 2018 Nov
TI  - Efficacy of tasquinimod in men with metastatic castration-resistant prostate 
      cancer: A meta-analysis of randomized controlled trials.
PG  - e13204
LID - 10.1097/MD.0000000000013204 [doi]
LID - e13204
AB  - BACKGROUND: Tasquinimod is an oral quinoline-3-carboxamide derivative for the 
      treatment of metastatic castration-resistant prostate cancer (mCRPC). Tasquinimod 
      has antiangiogenic, immunomodulatory, and antimetastatic properties, but it is 
      also associated with toxicities, including skeletal pain, digestive disorders, 
      fatigue, insomnia, and mental disorders. We aimed to perform a meta-analysis to 
      evaluate the efficacy, safety, and long-term survival for tasquinimod in patients 
      with mCRPC. METHODS: Searches were carried out in PubMed, Embase, and the 
      Cochrane Library. Eligible articles included randomized clinical trials (RCTs) 
      comparing systemic or combination therapy (excluding primary or secondary 
      androgen deprivation therapy, bone protective agents, or radionuclides) with 
      placebo in men with mCRPC. RESULTS: Three RCTs were selected for final 
      evaluation. The pooled results from the 3 studies indicated that tasquinimod was 
      associated with good radiologic progression-free survival (rPFS) in mCRPC. For 
      adverse effects (AEs), the results of meta-analysis indicated that patients with 
      mCRPC who received tasquinimod had obvious anemia (risk ratio (RR) 1.35, 95% 
      confidence interval (CI) 1.06-1.73, P = .02), back pain (RR: 1.57, 95% CI: 
      1.01-2.47, P = .05), pain in the extremities (RR: 1.90, 95% CI: 1.14-3.17, 
      P = .01), insomnia (RR: 1.50, 95% CI: 1.03-2.17, P = .03), vomiting (RR: 1.52, 
      95% CI: 1.04-2.21, P = .03), and peripheral edema (RR: 1.52, 95% CI: 1.03-2.23, 
      P = .03). CONCLUSIONS: Tasquinimod is associated with better rPFS in mCRPC. The 
      toxicity of tasquinimod requires further investigation, it is not recommended for 
      routine clinical use.
FAU - Gong, Ping
AU  - Gong P
AD  - Department of Epidemiology and Biostatistics.
FAU - Liu, Hongjian
AU  - Liu H
AD  - Department of Epidemiology and Biostatistics.
FAU - Liu, Xinyu
AU  - Liu X
AD  - Department of Epidemiology and Biostatistics.
FAU - Zhou, Ge
AU  - Zhou G
AD  - Department of Epidemiology and Biostatistics.
FAU - Liu, Meitian
AU  - Liu M
AD  - Department of Epidemiology and Biostatistics.
FAU - Yang, Xiaodi
AU  - Yang X
AD  - Department of Epidemiology and Biostatistics.
FAU - Xiong, Wenjing
AU  - Xiong W
AD  - Department of Epidemiology and Biostatistics.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Epidemiology and Biostatistics.
FAU - Ma, Juan
AU  - Ma J
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Jilin University, Changchun, Jilin, China.
FAU - Ren, Zheng
AU  - Ren Z
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Jilin University, Changchun, Jilin, China.
FAU - He, Minfu
AU  - He M
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Jilin University, Changchun, Jilin, China.
FAU - Zhang, Xiumin
AU  - Zhang X
AD  - Department of Social Medicine and Health Management, School of Public Health, 
      Jilin University, Changchun, Jilin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Quinolones)
RN  - 756U07KN1R (tasquinimod)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms, Castration-Resistant/*drug therapy/mortality
MH  - Quinolones/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC6257339
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/11/16 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/11/16
CRDT- 2018/11/16 06:00
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/11/16 00:00 [pmc-release]
AID - 00005792-201811160-00037 [pii]
AID - MD-D-18-03799 [pii]
AID - 10.1097/MD.0000000000013204 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Nov;97(46):e13204. doi: 10.1097/MD.0000000000013204.